Latest News - Clinical Trials

Friday, December 15, 2017 | Clinical Trials

Aura Biosciences Announces Publication of Preclinical Data Supporting AU-011’s Potent and Selective Anti-Cancer Activity in Ocular Melanoma Tumors

Aura Biosciences, announced that researchers at Massachusetts Eye and Ear (MEE), Emory University and the National Cancer Institute (NCI) have generated preclinical data that demonstrate the…

Read the full story

Tuesday, December 12, 2017 | Clinical Trials

Realm Therapeutics Announces First Patient Dosed in Phase 2 Study of PR013 for the Treatment of Allergic Conjunctivitis

Realm Therapeutics announced the first patient has been dosed in its phase 2 study of PR013, the company's topical ophthalmic formulation of high concentration hypochlorous acid, for the treatment…

Read the full story

Friday, December 08, 2017 | Clinical Trials, ThromboGenics

ThromboGenics: Patient Enrollment in Phase 2 CIRCLE Study Evaluating Ocriplasmin for Nonproliferative Diabetic Retinopathy Discontinued

ThromboGenics announced that it has discontinued patient recruitment in its phase 2 CIRCLE study for nonproliferative diabetic retinopathy (NPDR), effective immediately, due to the trial’s slow …

Read the full story

Tuesday, December 05, 2017 | Clinical Trials

Realm Therapeutics Announces First Patient Dosed in Phase 2 Study of PR022 for the Treatment of Atopic Dermatitis

Realm Therapeutics announced the first patient has been dosed in its phase 2 study of PR022, the company's proprietary topical gel formulation of high concentration hypochlorous acid, for the trea…

Read the full story

Wednesday, November 29, 2017 | Clinical Trials, Aldeyra Therapeutics

Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data

Aldeyra Therapeutics presented new statistical analyses of the results of a randomized, multicenter, investigator-masked, comparator-controlled, parallel-group phase 2 clinical trial of topical o…

Read the full story

Monday, November 27, 2017 | Clinical Trials, Medical Studies, Bio-Tissue

Bio-Tissue Announces Study that Demonstrates Cryopreserved Amniotic Membrane Graft Reduces Recurrence After Pterygium Surgery

Bio-Tissue announced study findings that show that the use of cryopreserved amniotic membrane reduces recurrence rates after pterygium surgery. In this retrospective review, published in the journa…

Read the full story

Monday, November 27, 2017 | Clinical Trials, Regeneron Pharmaceuticals

Regeneron Ends Clinical Program of Eylea and Nesvacumab (Ang2 Antibody) Combination

Regeneron announced that results from two phase 2 studies that added the angiopoietin2 (Ang2) antibody nesvacumab to Eylea (aflibercept) injection did not provide sufficient differentiation to warrant…

Read the full story

Tuesday, November 21, 2017 | Clinical Trials

Nevakar Announces First Subject Dosed in its Phase 3 Clinical Trial of NVK-002 for the Treatment of Myopia in Children

Nevakar announced that the first subject has been dosed in a phase 3 clinical trial of NVK-002, the company's investigational, topical ophthalmic solution intended to slow the progression of myopi…

Read the full story

Friday, November 17, 2017 | Clinical Trials, Glaucoma, Implandata Ophthalmic Products, IOP

Successful First-in-Human Testing of Implandata’s Next-Generation Eyemate Micro-Sensor for Improved Monitoring of Glaucoma Patients

Implandata Ophthalmic Products reported that its next-generation Eyemate micro-sensor implant for intraocular placement has successfully passed first-in-human validation.  “Thi…

Read the full story

Monday, November 13, 2017 | Clinical Trials, Clearside Biomedical

Clearside Biomedical’s Phase 1/2 Open-Label Clinical Trial of CLS-TA With and Without Eylea in DME Presented at AAO

Charles C. Wykoff, MD, PhD, presented preliminary results from an exploratory clinical trial (the HULK trial) of CLS-TA, Clearside’s proprietary suspension formulation of the corticosteroid tria…

Read the full story

Monday, November 13, 2017 | Clinical Trials, Retina, Novartis

Novartis: Brolucizumab (RTH258) Demonstrates Superiority Versus Aflibercept in Key Secondary Endpoint Measures of Disease Activity in nAMD

Novartis announced further positive results from two phase 3 studies of brolucizumab versus aflibercept (Eylea). Results showed noninferiority in primary endpoint, superiority in key retinal health ou…

Read the full story

Saturday, November 11, 2017 | Clinical Trials, Glaucoma, Ivantis

Ivantis FDA Clinical Trial of the Hydrus Microstent for Minimally Invasive Glaucoma Surgery Meets Endpoints, Exceeds Outcomes of Past MIGS Trials

Ivantis announced that the HORIZON pivotal study has met both the 2-year primary and secondary pre-established endpoints. Outcomes exceed those of any MIGS pivotal trial to date. Ivantis previously an…

Read the full story

Saturday, November 11, 2017 | Clinical Trials, Glaucoma

Ivantis FDA Clinical Trial of the Hydrus Microstent for Minimally Invasive Glaucoma Surgery (MIGS) Meets Endpoints, Exceeds Outcomes of Past MIGS Trials

Ivantis, developer of the Hydrus Microstent, announced that the HORIZON pivotal study has met both the 2-year primary and secondary pre-established endpoints. Outcomes exceed those of any MIGS pivotal…

Read the full story

Saturday, November 11, 2017 | Clinical Trials

Aura Biosciences Announces Interim Phase 1b/2 Data on Light-Activated AU-011 for Primary Ocular Melanoma

Aura Biosciences announced interim safety data from an open-label phase 1b/2 study of its lead program, light-activated AU-011, for the treatment of primary ocular melanoma. The findings were presente…

Read the full story

Friday, November 10, 2017 | Clinical Trials, Retina, Spark Therapeutics

Three-year Follow-up Phase 3 Data Provide Additional Information on Luxturna in Patients with Biallelic RPE65-Mediated Inherited Retinal Disease

Spark Therapeutics announced new 3-year follow-up data from the continuing phase 3 trial of Luxturna (voretigene neparvovec), an investigational, potential one-time gene therapy for the treatment of p…

Read the full story
Load More